Aurinia Pharmaceuticals (AUPH) Depreciation and Depletion (2020 - 2024)
Aurinia Pharmaceuticals (AUPH) posted Depreciation and Depletion of -$14.0 million for Q4 2024, down 385.78% on a QoQ basis from $4.9 million in Q3 2024, and down 129.3% year-over-year from $47.7 million in Q1 2024.
Aurinia Pharmaceuticals (AUPH) Depreciation and Depletion (2020 - 2024) Analysis & Trends
Aurinia Pharmaceuticals' Depreciation and Depletion history runs 5 years deep, the most recent figure standing at -$14.0 million for Q4 2024.
- Quarterly Depreciation and Depletion fell 129.3% year-over-year to -$14.0 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $600000.0 (changed 0.0% YoY) and the FY2025 annual result came in at $600000.0, changed 0.0% from the prior year.
- Depreciation and Depletion was -$14.0 million for Q4 2024 at Aurinia Pharmaceuticals, down from $4.9 million in the prior quarter.
- Across five years, Depreciation and Depletion topped out at $5.3 million in Q3 2023 and bottomed at -$14.0 million in Q4 2024.
- A 5-year average of $88411.8 and a median of $687000.0 in 2022 frame the typical range for Depreciation and Depletion.
- Annual changes were most pronounced in 2021 — Depreciation and Depletion plunged 7494.44% — and 2024, when it jumped 576.01%.
- Aurinia Pharmaceuticals' Depreciation and Depletion stood at -$18000.0 in 2020, then plunged by 7494.44% to -$1.4 million in 2021, then tumbled by 38.04% to -$1.9 million in 2022, then sank by 223.16% to -$6.1 million in 2023, then tumbled by 129.3% to -$14.0 million in 2024.
- Business Quant data shows AUPH's Depreciation and Depletion at -$14.0 million in Q4 2024, $4.9 million in Q3 2024, and $4.8 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 39.39 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Aurinia Pharmaceuticals | 2.02 Bn | 1.64 Bn | 71.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -13.98 Mn |
| Dec 31, 2024 | -13.98 Mn |
| Sep 30, 2024 | 4.89 Mn |
| Sep 30, 2024 | 4.89 Mn |
| Jun 30, 2024 | 4.84 Mn |
| Jun 30, 2024 | 4.84 Mn |
| Mar 31, 2024 | 4.85 Mn |
| Mar 31, 2024 | 4.85 Mn |
| Dec 31, 2023 | -6.10 Mn |
| Dec 31, 2023 | -6.10 Mn |
| Sep 30, 2023 | 5.26 Mn |
| Sep 30, 2023 | 5.26 Mn |
| Jun 30, 2023 | 719,000.00 |
| Jun 30, 2023 | 719,000.00 |
| Mar 31, 2023 | 717,000.00 |
| Mar 31, 2023 | 717,000.00 |
| Dec 31, 2022 | -1.89 Mn |
| Dec 31, 2022 | -1.89 Mn |
| Sep 30, 2022 | 1.11 Mn |
| Sep 30, 2022 | 1.11 Mn |